BioCentury | Jun 24, 2020

AsclepiX aims for basket of retinal indications with $35M series A

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology. Spun out of The...
BC Innovations | Jan 31, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Choroidal neovascularization (CNV); retinal detachment In vitro and mouse studies suggest the COL4A5 -mimetic peptide AXT107 could help treat CNV and retinal detachment. In vitro , AXT107 bound integrins α v β 3 and α...
Items per page:
1 - 2 of 2